TY  - JOUR
AU  - Herrero-Fernandez, Ines
AU  - Pacheco, Yolanda M.
AU  - Genebat, Miguel
AU  - Rodriguez-Mendez, Maria del Mar
AU  - Lozano, Maria del Carmen
AU  - Polaino, Maria Jose 
AU  - Rosado-Sanchez, Isaac
AU  - Tarancon-Diez, Laura
AU  - Munoz-Fernandez, Maria Angeles
AU  - Ruiz-Mateos, Ezequiel
AU  - Leal, Manuel
PY  - 2018
DO  - 10.1128/AAC.02050-17
SN  - 0066-4804
UR  - http://hdl.handle.net/10668/19009
T2  - Antimicrobial agents and chemotherapy
AB  - The response to the HBV vaccine in HIV-infected patients is deficient. Our aim was to analyze whether a suppressive combined antiretroviral treatment (cART) containing maraviroc (MVC-cART) was associated with a better response to HBV vaccine....
LA  - en
PB  - American Society for Microbiology
KW  - maraviroc
KW  - vaccine
KW  - HIV infection
KW  - combined antiretroviral treatment
KW  - hepatitis A virus
KW  - hepatitis B virus
KW  - Hiv-infected patients
KW  - Immune-responses
KW  - High-rates
KW  - Nonresponders
KW  - Adults
KW  - Immunosenescence
KW  - Progression
KW  - Blockade
KW  - Efficacy
KW  - Humans
KW  - Middle Aged
KW  - Maraviroc
KW  - Immunization, Secondary
KW  - Hepatitis B virus
KW  - Vaccines
KW  - Immunologic Factors
KW  - Vaccination
KW  - Hepatitis B Antibodies
KW  - HIV Infections
KW  - Demography
TI  - Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response
TY  - research article
VL  - 62
ER  -